Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
What is the dosing regimen for Taltz® (ixekizumab) in pediatric psoriasis?
160 mg at week 0, then 80 mg every 4 weeks for children greater than 50 kg body weight or 80 mg at week 0, then 40 mg every 4 weeks for children 25-50 kg body weight.
UK_cFAQ_IXE046_Y1_DOSING_PREPARATION_ADMINISTRATION_PEDS
en-GB
Recommended Pediatric Plaque Psoriasis Dosing Regimen
Children’s body weight |
Recommended starting dose (week 0) |
Recommended dose every 4 weeks (Q4W) thereafter |
Greater than 50 kg |
160 mg (two 80 mg injections) |
80 mg |
25 to 50 kg |
80 mg |
40 mg |
Children below 25 kg
Ixekizumab is not recommended for use in children with a body weight below 25 kg. Paediatric body weights must be recorded and regularly re-checked prior to dosing.1
Efficacy and safety data is not available in children below the age of 6 years.1
Available data do not support a posology below a body weight of 25 kg.1
Ixekizumab 40 mg Dose Preparation and Administration for Children 25-50 kg Body Weight
Ixekizumab doses of 40 mg must be prepared and administered by a qualified healthcare professional. Use only Taltz 80 mg solution for injection in pre-filled syringe when preparing the prescribed 40 mg paediatric doses.1
Necessary supplies (not provided with ixekizumab PFS) and dosing preparation steps for pediatric psoriasis patients weighing 25-50 kg are detailed in
The prepared ixekizumab must be administered within 4 hours of puncturing the sterile vial at room temperature.1
Method of Administration
Ixekizumab is for subcutaneous injection. Injection sites may be alternated. If possible, areas of the skin that show psoriasis should be avoided as injection sites. The solution/the syringe must not be shaken.1
After proper training in subcutaneous injection technique, patients may self-inject ixekizumab if a healthcare professional determines that it is appropriate. However, the physician should ensure appropriate follow-up of patients. Comprehensive instructions for administration are given in the package leaflet and the user manual.1
Doses less than 80 mg which require dose preparation should only be administered by a healthcare professional.1
Weight Category Changes
In the IXORA-PEDS clinical trial, if a subject changed weight category, the ixekizumab dose associated with the most current weight was administered for all periods except the 12-week double-blind treatment period.2
References
1Taltz [summary of product characteristics]. Eli Lilly and Company (Ireland) Limited, Ireland
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
PFS = prefilled syringe
SC = subcutaneous
Date of Last Review: 14 May 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays